Skip to main content
OpenTrials
Recruiting

NCT Number: NCT04735263

Dark Adaptation as an Early Indicator of Response to Statin Therapy for Intermediate AMD

interventional trial for off label use of high dose atorvastatin 80 mg in intermediate AMD patients and correlate recovery response measured by dark adaptation recovery time with drusen volume reduction measured by SD-OCT

Recruiting

Interested in participating?

Request Info

Key information

Age range

50 year–85 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Primary location

Massachusetts Eye and Ear Infirmary

Boston, Massachusetts, 02114, United States

Location status: Recruiting

Location contact

John B Miller, MD

CONTACT

[email protected]

617-573-3750

About this study

Dark adaptation recovery time is a sensitive marker of AMD progression in intermediate AMD, largely owing to drusen volume providing a transport barrier that slows the transfer of nutrients between the choroid and photoreceptors2. Consequently, dark adaptation may provide an early indication of response vs. nonresponse, aiding case-by-case decisions on continuation of treatment when patients experience adverse side effects (e.g., elevated CPK or liver enzymes) or when atorvastatin provides insufficient lipid control in patients also at high-risk for cardiovascular disease (and switching to an alternative statin might be desirable).

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • All subjects with intermediate AMD diagnosis in one or both eyes will be considered, regardless the severity stage and subtype of disease in the other eye.

High-risk iAMD (numerous large, confluent drusen covering ≥ 0.5 disk area, with or without pigmentary changes but having no evidence of GA or CNV) in the study eye

Subjects can have either:

(i) Bilateral high-risk iAMD, or (ii) High-risk iAMD in one eye with GA and/or CNV in the fellow eye.

Exclusion criteria

  • Patient previously taking high dose Atorvastatin 80 mg
  • Patients previously taking other statins than high dose atorvastatin, in whom primary care provider (PCP) feels cannot be safely moved to high dose atorvastatin or those in which high dose atorvastatin is deemed contraindicated by PCP
  • Patients with known adverse reaction to statins
  • Patients with severe renal disease or multiple comorbidities
  • Age >85 years
  • Pregnancy
  • Patients with concomitant use of cyclosporine
  • Active uveitis;
  • Ocular infection;
  • Any retinopathy other than AMD;
  • Media opacities;
  • Refractive error equal or superior to 6 diopters (spherical equivalent);
  • Any previous retina surgery;
  • Other ocular surgery or intra-ocular procedure in the study eye (injection other than anti angiogenic injection, laser) within the 90 days prior to enrollment

Treatment and study plan

Atorvastatin 80mg

Drug

Patient will be receiving 80mg of Atorvastatin, if they are able to tolerate it from the start to the end of the study.

Other names: Lipitor 80 mg(Brand name)

Primary outcomes

  1. Change in Dark Adaptation recovery time measured by change in Rod Intercept time (RIT)

    Time frame: 18 Months

    Determine weather improvement in dark adaptation recovery time or rod intercept time (RIT) can be used as an early indicator of positive response to high dose statin therapy for intermediate AMD patients

  2. Change in drusen volume measured by Spectral Domain OCT

    Time frame: 18 months

    To measure and quantify improvement or positive response to high dose statin therapy in patients with intermediate AMD using drusen volume measured by SDOCT

  3. To correlate visual functions of dark adaption with change in drusen volume

    Time frame: 18 months

    Patient will have Dark Adaptation testing performed to check change in vision function with changes in drusen volume.

Secondary outcomes

  1. To correlate Best Corrected Visual Acuity and retinal structural evaluation of study patients

    Time frame: 18 months

    Patient will have Best Corrected visual acuity, testing performed to check changes in vision function

  2. To correlate change in contrast sensitivity and retinal structural evaluation of study patients

    Time frame: 18 months

    Patient will have quantitative contrast sensitivity function testing performed to check change in vision function with changes in drusen volume.

  3. To correlate change in microperimetry visual functional and retinal structural evaluation of study patients

    Time frame: 18 months

    Patient will have microperimetry function testing performed to check change in this vision function with changes in drusen volume

Study contacts

Contact information is provided by the study sponsor or research team.

Deeba Husain

CONTACT

[email protected]

617-573-3750

John B Miller, MD

CONTACT

[email protected]

617-573-3750

Sponsors and collaborators

Lead sponsor

Massachusetts Eye and Ear Infirmary

Other

Registry information

Acronym: DELPHI

Important dates

Study start
2021
Primary completion
2027
Study completion
2028
First posted
Feb 3, 2021
Registry last updated
Jan 26, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.